Northern Trust Corp Acquires 22,266 Shares of Harrow, Inc. (NASDAQ:HROW)

Northern Trust Corp boosted its holdings in Harrow, Inc. (NASDAQ:HROW - Free Report) by 7.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 319,084 shares of the company's stock after purchasing an additional 22,266 shares during the quarter. Northern Trust Corp owned about 0.90% of Harrow worth $10,705,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Tower Research Capital LLC TRC grew its position in Harrow by 769.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock valued at $55,000 after purchasing an additional 1,462 shares during the period. Aquatic Capital Management LLC acquired a new stake in Harrow in the 4th quarter valued at $78,000. AlphaQuest LLC grew its position in Harrow by 452.8% in the 4th quarter. AlphaQuest LLC now owns 3,527 shares of the company's stock valued at $118,000 after purchasing an additional 2,889 shares during the period. Federated Hermes Inc. acquired a new stake in Harrow in the 4th quarter valued at $214,000. Finally, Maridea Wealth Management LLC acquired a new stake in Harrow in the 4th quarter valued at $222,000. Institutional investors and hedge funds own 72.76% of the company's stock.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. HC Wainwright lifted their price target on shares of Harrow from $57.00 to $60.00 and gave the company a "buy" rating in a research report on Monday, May 12th. B. Riley dropped their price objective on Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st.

Harrow Stock Up 0.6%

NASDAQ:HROW traded up $0.16 during trading hours on Friday, hitting $25.90. 417,482 shares of the company traded hands, compared to its average volume of 497,258. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. The firm's 50-day simple moving average is $25.36 and its 200-day simple moving average is $31.36. Harrow, Inc. has a one year low of $16.71 and a one year high of $59.23. The company has a market cap of $950.14 million, a PE ratio of -27.55 and a beta of 0.41.

Harrow (NASDAQ:HROW - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of $0.02 by ($0.40). Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The company had revenue of $47.83 million for the quarter, compared to the consensus estimate of $57.00 million. Equities analysts predict that Harrow, Inc. will post -0.53 earnings per share for the current year.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.